Hinge Bio

Executive Summary

Hinge Bio is a privately-held biotechnology company founded in 2019 and headquartered in San Diego, California. The company is developing next-generation antibody therapeutics leveraging its proprietary GEM-DIMER™ platform, which enables the design of antibodies with superior properties such as enhanced potency, specificity, and half-life. Hinge Bio focuses on therapies for autoimmune, inflammatory diseases, and cancer. The platform's versatility allows it to address multiple targets and indications, positioning the company as a potential leader in the biologics space. Although still in preclinical stages and lacking disclosed pipeline details, Hinge Bio's innovative approach and experienced team have attracted interest from investors and potential partners. The company operates in a competitive landscape but differentiates itself through its dimerization technology that enhances therapeutic efficacy and reduces immunogenicity.

Upcoming Catalysts (preview)

• H2 2026IND Filing for Lead Antibody Candidate55% success
• Q4 2026Presentation of Preclinical Data at Major Scientific Conference80% success
• 2026Strategic Partnership or Licensing Deal40% success